

insurance issuers. Nominations should be sent to the email or mailing address listed below. Acknowledgement of submissions will be provided within a week of submission.

DATES: Letters of nomination and résumés should be submitted no later than May 13, 2020, to ensure adequate opportunity for review and consideration of nominees prior to appointment.

ADDRESSES: Submit letters of nomination and résumés by either of the following methods:

Email: PCORI@gao.gov. Include PCORI Nominations in the subject line of the message, or Mail: U.S. GAO, Attn: PCORI Nominations, 441 G Street NW, Washington, DC 20548.

FOR FURTHER INFORMATION CONTACT: Ray Sendejas at (202) 512-7113 or sendejasr@gao.gov if you do not receive an acknowledgement or need additional information. For general information, contact GAO's Office of Public Affairs, (202) 512-4800.

Authority: Sec. 6301 and Sec. 10602, Pub. L. 111-148, 124 Stat. 119, 727, 1005 (2010); Div. N, Sec. 104, Pub. L. 116-94, 133 Stat. 2534 (2019).

Gene L. Dodaro,

Comptroller General of the United States.

[FR Doc. 2020-06313 Filed 3-31-20; 8:45 am]

BILLING CODE 1610-02-P

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Centers for Disease Control and Prevention

Disease, Disability, and Injury Prevention and Control Special Emphasis Panel (SEP) GH20-001, Develop, Implement, and Evaluate Evidence-Based, Innovative Approaches To Prevent, Find, and Cure Tuberculosis in High-Burden Settings; GH20-002, Malaria Operations Research To Improve Malaria Control and Reduce Morbidity and Mortality in Western Kenya; GH20-003, Conducting Public Health Research in Colombia; GH20-004, Conducting Public Health Research in Georgia; and GH20-005, Conducting Public Health Research in South America; Amended Notice of Meeting

Notice is hereby given of a change in the meeting of the Disease, Disability, and Injury Prevention and Control Special Emphasis Panel (SEP)—GH20-001, Develop, Implement, and Evaluate Evidence-Based, Innovative Approaches to Prevent, Find, and Cure Tuberculosis in High-Burden Settings; GH20-002,

Malaria Operations Research to Improve Malaria Control and Reduce Morbidity and Mortality in Western Kenya; GH20-003, Conducting Public Health Research in Colombia; GH20-004, Conducting Public Health Research in Georgia; and GH20-005, Conducting Public Health Research in South America; April 14-16, 2020, 9:00 a.m.–2:00 p.m., EDT, in the original FRN.

Teleconference, which was published in the **Federal Register** on March 16, 2020, Vol. 85, No. 51, page 14946.

The meeting is being amended to change the meeting dates and times to: April 14-15, 2020, from 9:00 a.m.–2:00 p.m., EDT; and April 16, 2020, from 9:30 a.m.–2:30 p.m., EDT. The meeting is closed to the public.

FOR FURTHER INFORMATION CONTACT: Hylan Shoob, Ph.D., Scientific Review Officer, Center for Global Health, CDC, 1600 Clifton Road NE, Atlanta, Georgia 30329-4027, Telephone (404) 639-4796; HShoob@cdc.gov.

The Director, Strategic Business Initiatives Unit, Office of the Chief Operating Officer, Centers for Disease Control and Prevention, has been delegated the authority to sign **Federal Register** notices pertaining to announcements of meetings and other committee management activities, for both the Centers for Disease Control and Prevention and the Agency for Toxic Substances and Disease Registry.

Kalwant Smagh,

Director, Strategic Business Initiatives Unit, Office of the Chief Operating Officer, Centers for Disease Control and Prevention.

[FR Doc. 2020-06780 Filed 3-31-20; 8:45 am]

BILLING CODE 4163-18-P

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Centers for Disease Control and Prevention

Disease, Disability, and Injury Prevention and Control Special Emphasis Panel (SEP)—TS-20-001, Identify and Evaluate Potential Risk Factors for Amyotrophic Lateral Sclerosis; Amended Notice of Meeting

Notice is hereby given of a change in the meeting of the Disease, Disability, and Injury Prevention and Control Special Emphasis Panel (SEP)—RFA-TS-20-001, Identify and Evaluate Potential Risk Factors for Amyotrophic Lateral Sclerosis; May 13, 2020, 1:00 p.m.–5:30 p.m., EDT, in the original FRN.

Teleconference, Centers for Disease Control and Prevention, 4770 Buford Highway NE, Atlanta, Georgia 30341,

which was published in the **Federal Register** on March 4, 2020, Volume 85, Number 43, pages 12786–12787.

The meeting is being amended to a virtual meeting with a meeting time of 9:30 a.m.–5:30 p.m., EDT. The meeting is closed to the public.

FOR FURTHER INFORMATION CONTACT:

Kimberly Leeks, Ph.D., M.P.H., Scientific Review Official, NCIPC, CDC, 4770 Buford Highway NE, Building 106, MS S106-9, Atlanta, Georgia 30341, telephone: (770) 488-6562; KLeeks@cdc.gov.

The Director, Strategic Business Initiatives Unit, Office of the Chief Operating Officer, Centers for Disease Control and Prevention, has been delegated the authority to sign **Federal Register** notices pertaining to announcements of meetings and other committee management activities, for both the Centers for Disease Control and Prevention and the Agency for Toxic Substances and Disease Registry.

Kalwant Smagh,

Director, Strategic Business Initiatives Unit, Office of the Chief Operating Officer, Centers for Disease Control and Prevention.

[FR Doc. 2020-06781 Filed 3-31-20; 8:45 am]

BILLING CODE 4163-18-P

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Centers for Medicare & Medicaid Services

[CMS-3389-FN]

Medicare Program; Approval of Application by the Utilization Review Accreditation Commission for Initial CMS-Approval of Its Home Infusion Therapy Accreditation Program

AGENCY: Centers for Medicare and Medicaid Services, HHS.

ACTION: Final notice.

SUMMARY: This final notice announces our decision to approve the Utilization Review Accreditation Commission (URAC) for initial recognition as a national accrediting organization for home infusion therapy suppliers that wish to participate in the Medicare program. A home infusion therapy supplier that participates must meet the Medicare conditions for coverage (CfCs).

DATES: The approval announced in this final notice is effective March 27, 2020 through March 27, 2024.

FOR FURTHER INFORMATION CONTACT:

Christina Mister-Ward, (410)786-2441. Lillian Williams, (410)786-8636.